Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Therapy

The ATTRACTION of nivolumab for gastric and gastro-oesophageal junction cancer

Phase III trial results reported in The Lancet indicate that immune checkpoint inhibition with nivolumab (a monoclonal antibody against PD1) could be a new treatment option for advanced gastric or gastro-oesophageal junction cancer. In the ATTRACTION-2 study, 493 patients with advanced gastric or gastro-oesophageal junction cancer who were refractory to, or intolerant of, two or more previous chemotherapy regimens were enrolled from across 49 clinical centres in Japan, South Korea and Taiwan. Patients were then randomly assigned to receive either nivolumab (n = 330) or placebo (n = 193). Median overall survival (5.26 months versus 4.14 months; P < 0.0001) and 12-month overall survival rates (26.2% versus 10.9%) were higher in the nivolumab group than in the placebo group.

References

  1. 1

    Kang, Y.-K. et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet http://dx.doi.org/10.1016/S0140-6736(17)31827-5 (2017)

Download references

Authors

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ray, K. The ATTRACTION of nivolumab for gastric and gastro-oesophageal junction cancer. Nat Rev Gastroenterol Hepatol 14, 690 (2017). https://doi.org/10.1038/nrgastro.2017.157

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing